中西医结合治疗顽固性心力衰竭患者的应用研究

发布时间：2018-02-24 04:45

本文关键词： 顽固性心力衰竭参松养心胶囊重组人脑钠利肽　出处：《中国现代医学杂志》2017年19期 　论文类型：期刊论文

【摘要】：目的探讨参松养心胶囊与重组人脑钠利肽在顽固性心力衰竭(以下简称心衰)患者中的联合应用价值。方法选取2013年1月-2014年12月南阳医学高等专科学校第一附属医院收治的顽固性心衰患者86例,分为治疗组和对照组各43例。对照组采用重组人脑利钠肽的临床药物治疗,治疗组在对照组治疗的基础之上加用参松养心胶囊的药物联合治疗,分别比较两组顽固性心衰患者的临床治疗效果。结果与对照组相比,治疗组临床治疗的总有效率(93.02%)提升,而无效率则(6.98%)减少,经过统计学处理,差异均具有统计学意义(P0.05);治疗组左室收缩末期内径(LVESD)(32.43±4.05)mm、左室舒张末期内径(LVEDD)(47.39±4.09)mm、左室收缩末期容积(LVESV)(66.03±12.09)ml、左室舒张末期容积(LVEDV)(86.41±13.52)ml均减少,而左室射血分数LVEF(48.64±6.98)%提高,经过统计学处理,差异均具有统计学意义(P0.05);治疗组心肌肌钙蛋白I(c Tn I)(0.29±0.10)μg/L、超敏C反应蛋白(hs-CRP)(9.65±3.21)mg/L、N末端B型利钠肽原(NT-pro BNP)(389.47±113.70)ng/L均降低,经过统计学处理,差异均具有统计学意义(P0.05)。结论参松养心胶囊与重组人脑钠利肽在顽固性心衰患者的联合治疗过程中,能够积极改善心功能指标,并有效调节神经内分泌因子,从根本上提高临床疗效。
[Abstract]:Objective to explore the combined application value of Shensong Yangxin capsule and recombinant human brain natriuretic peptide in patients with refractory heart failure. A total of 86 patients with refractory heart failure were admitted in our hospital. The patients were divided into treatment group (n = 43) and control group (n = 43). The control group was treated with recombinant human brain natriuretic peptide and the treatment group was treated with Shensong Yangxin capsule on the basis of the treatment of the control group. Results compared with the control group, the total effective rate of the treatment group was increased (93.02%), while the inefficiency rate was decreased (6.98%). In the treatment group, the left ventricular end-systolic diameter (LVESD) was 32.43 卤4.05 mm, the left ventricular end-diastolic diameter was 47.39 卤4.09 mm, the left ventricular end-systolic volume was 66.03 卤12.09 ml, the left ventricular end-diastolic volume was 86.41 卤13.52 ml, and the left ventricular ejection fraction (LVEF(48.64 卤6.98) was increased. The difference was statistically significant (P 0.05), the cardiac troponin I ~ (3 +) T _ (n) I ~ (1) (0.29 卤0.10) 渭 g 路L ~ (-1), the hypersensitive C-reactive protein (Hs-CRP) 9.65 卤3.21 mg 路L ~ (-1) N terminal natriuretic peptide (NT-pro BNP)(389.47 卤113.70 ng / L) were decreased in the treatment group. Conclusion Shensong Yangxin capsule and recombinant human brain natriuretic peptide can improve cardiac function index and regulate neuroendocrine factor effectively in the course of treatment of intractable heart failure. Fundamentally improve the clinical efficacy.
【作者单位】：南阳医学高等专科学校第一附属医院心血管内科;
【分类号】：R541.6

【相似文献】